Severity

A subset of Member States and areas monitors severe disease related to influenza virus infection by surveillance of 1) hospitalized laboratory-confirmed influenza cases in ICUs (12 Member States or areas), or other wards (8 Member States or areas), or 2) severe acute respiratory infection (SARI; 17 Member States or areas).

1.1) Hospitalized laboratory-confirmed influenza cases – ICUs

From week 21/2019 through week 25/2019 there have been 6 laboratory-confirmed influenza cases in ICUs, 5 were influenza A and 1 was influenza B. There were two influenza A viruses that were subtyped and both were influenza A(H3N2). The majority of these cases (67%) were among individuals aged 65 years and older, and 2 (33%) were among children aged 0-4 years.

1.2) Hospitalized laboratory-confirmed influenza cases – other wards

For week 21/2019 through week 25/2019 there have been 42 laboratory-confirmed influenza cases from other wards, 41 of which were influenza A. The majority of influenza A cases were not subtyped but of those that were (n=10) all were influenza A(H3N2). The majority (64%) of influenza cases reported were among indivdiuals age 65 years or greater.

2. SARI surveillance

For weeks 21-25/2019, 2 664 SARI cases were reported by 8 Member States or areas. Of these cases, 268 specimens were tested for influenza viruses and 8 (3%) tested positive for influenza, 5 were type B and 3 were type A. All influenza A viruses were subtype A(H3N2).

Mortality monitoring

For week 25/2019, the EuroMOMO project received data from 24 countries or areas that were included in pooled analyses. The pooled estimates indicated that all-cause mortality was within expected ranges.